Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. (ELVN) is a healthcare company (biotechnology) based in the United States. The share price is $46.97, down 1.36% on the day, which values the company at $3.46B. Price as of 17 Nov 2026, 19:14 UTC, from Yahoo Finance.

Key facts

Share price
$46.97−1.36% today
Market value
$3.46B
200-week average
$24.9888% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Enliven Therapeutics, Inc. in more detail

ELVN trades at -23.6× next year's expected earnings. It sits 88% above its 200-week average of $24.98.

In its favour: More cash than debt.

2 of the superinvestors tracked here hold ELVN, including Doug Silverman (0.3% of the portfolio), Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding ELVN

2 of the investors tracked here report a position in their latest 13F filing.

Enliven Therapeutics, Inc. (ELVN): questions and answers

What is Enliven Therapeutics, Inc.'s market cap?

Enliven Therapeutics, Inc. is valued at $3.46B at a share price of $46.97.

Is ELVN above its 200-week moving average?

Yes. ELVN is 88.0% above its 200-week average of $24.98. Long-term investors watch that line because strong companies rarely trade below it for long.

Does ELVN pay a dividend?

Enliven Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own ELVN?

In their latest quarterly filings, Doug Silverman (0.3% of the portfolio), Julian and Felix Baker (0.2% of the portfolio) hold ELVN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Enliven Therapeutics, Inc. (ELVN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ELVN

Underlying data: Yahoo Finance; company filings with the SEC.